Monday, January 30, 2023

J&J forecasts 2023 profit above expectations on pharma strength

Must read

Freed from iBuying, Zillow wants more from its mortgage arm in 2023

This is the ninth in a series of nine reports on the challenges the country’s largest brokerages, portals and iBuyers face in 2023....

Why this economist says today’s market is not a do-over of 2008

Now, although price growth through the pandemic period was clearly excessive, writes economist Matthew Gardner, fundamentally speaking, the two periods cannot be...

How to create great marketing content in seconds with ChatGPT

It’s Agent Appreciation Month here at Inman. Join us to celebrate all that agents do, all month long. Craving total access? Take advantage...

The new top 3 rules of real estate: Speed. Speed. Speed

Owning a home is the American dream. So why has the mortgage process always been such a nightmare? For agents, coaching...

J&J forecasts 2023 profit above expectations on pharma strength © Reuters. The U.S. flag is seen over the company logo for Johnson & Johnson to celebrate the 75th anniversary of the company’s listing at the New York Stock Exchange (NYSE) in New York, U.S., September 17, 2019. REUTERS/Brendan McDermid

(Reuters) -Johnson & Johnson on Tuesday forecast annual profit above Wall Street estimates, as steady demand for its drugs such as cancer treatment Darzalex is expected to help ease pressure from inflation and a strong dollar.

Shares of the drugmaker, however, fell 1% to $166.12 in premarket trading as fourth-quarter sales missed analysts’ estimates due to lower demand for its medical devices.

J&J (NYSE:) also expects sales of its medical devices to be lower in the first half of 2023 than in the second half, as surging COVID-19 cases in China limit medical procedures in hospitals.

Overall, the healthcare conglomerate posted better-than-expected quarterly earnings, helped by demand for Darzalex and its COVID-19 vaccine.

J&J expects to earn between $10.45 and $10.65 per share on an adjusted basis for 2023, above analysts’ estimates of $10.35 per share profit at the midpoint.

The higher 2023 profit forecast also reflects better-than-expected cost controls by J&J, Edward Jones analyst John Boylan said.

J&J’s large pharmaceuticals business is its major profit engine and the company is betting on that and its devices unit as the healthcare conglomerate prepares to spin off its consumer health business by the end of this year.

Pharmaceutical sales of $13.16 billion for the fourth quarter beat estimates of $13.14 billion. Darzalex sales were $2.08 billion, while analysts were expecting $2.02 billion, according to Refinitiv.

J&J also recorded $821 million in COVID-19 vaccine-related costs, which were related to changes in its research program and manufacturing capacity.

Excluding items, J&J earned $2.35 per share, above analysts’ average estimates of $2.23 per share, according to IBES data from Refinitiv.

More articles

Latest article

Freed from iBuying, Zillow wants more from its mortgage arm in 2023

This is the ninth in a series of nine reports on the challenges the country’s largest brokerages, portals and iBuyers face in 2023....

Why this economist says today’s market is not a do-over of 2008

Now, although price growth through the pandemic period was clearly excessive, writes economist Matthew Gardner, fundamentally speaking, the two periods cannot be...

How to create great marketing content in seconds with ChatGPT

It’s Agent Appreciation Month here at Inman. Join us to celebrate all that agents do, all month long. Craving total access? Take advantage...

The new top 3 rules of real estate: Speed. Speed. Speed

Owning a home is the American dream. So why has the mortgage process always been such a nightmare? For agents, coaching...

Social media tactics top agents rely on in their marketing plan

Join the exceptional and become a Sotheby's International Realty agent.Learn More Luxury real estate is built on relationships, and the best...